PCSK9 inhibitors are a class of drugs that specifically target the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme plays a crucial role in cholesterol metabolism by regulating the number of low-density lipoprotein (LDL) receptors on the surface of liver cells. By inhibiting PCSK9, these drugs increase the availability of LDL receptors, thus enhancing the clearance of LDL cholesterol from the blood.
